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neoplasms of the anterior mediastinum. They often invade locally, com-
monly metastasizing to regional lymph nodes. Distant metastases to 
bone, liver or skin can occur in 30 to 40% of cases and may be seen in 
just over two-thirds of patients within 8 years from initial diagnosis.
Complete surgical resection is the preferred method of treatment, 
although recurrence is common. Despite a lack of evidence, incomplete 
resections followed by radiation (and/or chemotherapy) have been used 
may improve local control without signiﬁcant increased morbidity and 
mortality. However, despite aggressive treatments, most patients do 
poorly; overall 5-year survival according to one report was almost one-
third, with all patients dead after about 9 years. 
Thoracic Radiation Toxicity and Tissue Tolerance 
Radiation therapy to the chest region can affect some of the major 
thoracic organs including the heart, spinal cord, lung, and esophagus. 
Acute symptoms include transient skin reactions, fatigue, cough, 
dysphagia, shortness of breath and dyspnea. Skin atrophy and hyper-
pigmentation, hair loss, telangiectasia, soft tissue fribrosisﬁbrosis may 
occur within the irradiated area, commonly with low energy beam 
therapy. Radiation damage to the ribs and spine appears late and may 
lead to spontaneous, radiation-induced osteoporosis and rib fracture 
within the treated area.
Cardiac irradiation can lead to pericardial disease, valvular and coro-
nary abnormalities, congestive heart failure, arrhythmias, restrictive 
myopathy and even myocardial infarction. Cardiovascular mortality 
can often be avoided by the use of appropriate techniques and avoid-
ance of excessive treatment of the entire heart volume as the risk of 
cardiotoxicity generally is low unless the dose to the entire cardiac 
volume exceeddose to the entire cardiac volume exceeds 40-50 Gy. 
The lung is relatively sensitive to radiation. When a large volume of the 
lung is irradiated, the patient may develop cough and dyspnea resulting 
in radiation pneumonitis, symptoms of which are similar to pneumonia, 
particularly when radiation therapy is delivered in large fraction size 
(>250 cGy) and combined with systemic chemotherapy.
Acute radiation pneumonitis can occur during radiation treatment or 
within a few weeks afterward. Chronic form may occur 4 to 6 months 
after competioncompletion of radiation therapy. Some of the risk 
factors include low pre-treatment performance status, co-morbid lung 
disease, smoking history, poor pulmonary function tests, large volume 
of lung receiving 20 Gy or more, and large fraction size. Radiographic 
differentiation of radiation-induced pulmonary effects from recurrent, 
metastatic disease, or new malignancies can be difﬁcult. Acute radia-
tion changes can be seen as radiographic opacities within the radiation 
treatment boundaries. With time, increased lung density, loss of lung 
volume, and pleural thickening may develop. Although out-of-ﬁeld 
radiation pneumonitis can occur, distinct conﬁnement of these ﬁndings 
within the irradiated volume suggests of radiation-induced changes. 
Most patients with radiation pneumonitis will recovery with early diag-
nosis and proper management with antibiotics and steroids.
Late effects of radiation injury on the mucosa of the aerodigestive tract 
can lead to decreased mucosal pliability, ﬁbrosis and, occasionally, 
chronic ulceration, ﬁstula and necrosis. These are uncommon sequelae 
in the treatment of thymic tumors, but may be seen after high dose of 
radiationof radiation targeted at the esophagus. 
Radiation myelitis is very rare when the dose to the spinal cord is lim-
ited to no more 45 Gy at standard fractionation. Infrequently, radiation-
induced secondary neoplasms may develop in young patients receiving 
radiation therapy. The latency period is often long (>10 years). Radia-
tion-induced sarcomas are more common and well-recognizedwell 
recognized as one of the late complications of radiation therapy. Other 
tumors due to chest radiation therapy include skin, lung, and bone 
tumors. For female patients, chest irradiation can lead to a higher risk 
of developing breast cancer. 
With a number of deciding factors and signiﬁcant variations among 
individual patients, the total dose, number of treatments and ﬁeld size 
must be individualized to maximize the therapeutic effect to provide 
local control and minimize the side effects, patient inconvenience, and 
potential expense of treatment. The risk of late sequelae is generally 
low when proper radiation technique is employed. The ongoing im-
provement in radiation delivery (e.g. 3-D conformal radiation therapy, 
Intensity Modulated Radiation Therapy) will likely decrease the risks 
of radiation complications. 
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The majority of thymic tumors present in an early stage and can be 
cured with primary surgery, with or without post-operative radiation. 
For these tumors, chemotherapy is rarely necessary. However, in the 
management locally-advanced thymic tumors that are either unresect-
able or of borderline resectability, or in the treatment of thymic tumors 
with distant metastases, systemic treatments are a critical component. 
Thymic tumors are relatively sensitive to cytotoxic chemotherapy. 
Because of the rarity of thymic tumors, there is a paucity of random-
ized, phase III data. Phase II studies have shown that chemotherapy 
can shrink tumors and palliate symptoms in patients with advanced 
thymic tumors. The most active single agents for thymic tumors in-
clude cisplatin, ifosfamide, and doxorubicin. Compared to single agent 
chemotherapy, combination chemotherapy leads to improved response 
rates and, in a retrospective series, to improved overall survival[1]. The 
best results for chemotherapy in thymic tumors have been obtained 
with the PAC regimen (cisplatin, doxorubicin, and cyclophosphamide) 
and the ADOC regimen (cisplatin, doxorubicin, vincristine, and cyclo-
phosphamide) with response rates in the metastatic setting of 50% to 
91%[2, 3]. The combination of cisplatin and etoposide also has activity 
in advanced thymic tumors[4]. The addition of ifosfamide to platinum-
based chemotherapy increases toxicity but does not appear to improve 
outcomes in a phase II study[5]. The Eastern Cooperative Oncology 
Group (ECOG) is currently evaluating the combination of carboplatin 
and paclitaxel in advanced thymic tumors. 
Patients who progress following initial chemotherapy may respond 
to re-treatment with the same regimen, particularly if they enjoyed a 
prolonged (greater than 12-month) progression-free interval[6]. Some 
patients respond to steroids[7]. Thymic tumors have been shown to 
possess receptors for somatostatin[8], and an ECOG study of octreotide 
in invasive, recurrent, or metastatic thymoma or thymic carcinoma 
produced a response rate of 30% with a stable disease rate of 37%[9]. 
Induction therapy for locally-advanced thymic tumors may be able to 
convert patients from unresectable to resectable. A phase II study of 
neoadjuvant ADOC in patients with stage III and IV thymomas dem-
onstrated a partial reponse rate of 100%, a 43% complete radiographic 
response, a pathologic complete response at the time of surgery of 31%, 
and a three-year survival of 70%[10]. A phase II study of PAC plus 
prednisone in stage III and IVA thymoma patients produced a partial 
response rate of 67%, a 14% complete radiographic response rate, a 
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complete pathologic response rate of 9.5% , and 7-year disease-free and 
overall-survival rates of 77% and 79% respectively[11, 12]. 
In general, it is recommended that patients with locally-advanced 
thymic tumors that initially appear inoperable undergo induction che-
motherapy with reassessment for potential surgical resection following 
chemotherapy. A prospective study of a multimodality management 
strategy in thymic tumors found that, compared to historical controls, 
chemotherapy and radiation following surgery appeared to improve 
outcomes for medium risk and high risk thymic tumors[13]. Medium 
risk thymic tumors were deﬁned as stage I and II cortical thymomas/
thymic carcinomas or stage II mixed thymoma, and high risk tumors 
were deﬁned as stage III and IV cortical thymomas/thymics carcinoma 
and stage III mixed thymomas. 
Patients with locally advanced thymic tumors who remain unresectable 
following induction chemotherapy may still be approached with cura-
tive intent via aggressive thoracic radiation. In a phase II Intergroup 
study evaluating 54Gy of radiation following two to four cycles of 
induction PAC (with additional chemotherapy administration following 
radiation), the 5-year failure-free survival was 54% while the median 
time to treatment failure was 93 months[14]. 
Thymic carcinomas appear histologically malignant and follow a more 
aggressive clinical course than thymomas. They display a greater ten-
dency for hematogenous metastasis and carry a worse prognosis. Given 
the rarity of this histologic subtype, prospective phase II studies of 
chemotherapy in only thymic carcinomas are rare. Nonetheless, it does 
appear that while thymic carcinomas are less responsive to chemothera-
py than thymomas, responses nonethless can and do occur[1, 15, 16].
While thymomas and thymic carcinomas can respond to chemotherapy, 
it is critical to remember that chemotherapy is not a cure for widely 
metastatic disease. Thymomas in particular can exhibit an indolent 
course with patients remaining asymptomatic for extended periods 
of time. Therefore, the judicious use of watchful waiting interspersed 
with intermittent, appropriately-timed chemotherapy can optimize the 
survival, symptom palliation, and quality of life for these patients.
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There is convincing clinical evidence that image guided radiotherapy 
can substantially increase the therapeutic ratio for a number of dif-
ferent cancer sites. Image guided radiotherapy is a fast-growing and 
technically complex ﬁeld, with many available commercial options to 
improve beam-target alignment. There is also substantial research and 
development into improved image guided technologies. The clinical 
rationale, current available solutions and future prospects of image 
guided therapy will be discussed. 
Educational objectives:
(1) Understand the clinical rationale for improved target accuracy in 
radiotherapy
(2) Describe several available technologies that perform image-guided 
radiotherapy
(3) Understand future developments in image guided radiotherapy
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Introduction: Stereotactic body radiotherapy (SBRT) is a new tech-
nique, introduced in the late 1990s. SBRT is a method of using single 
10-20Gy of high dose and hypofractionated radiotherapy using three-
dimensional conformal technique. Several respiratory regulation meth-
ods have been developed. Recently, many papers have been published 
on its clinical results, in early-stage lung cancer, liver cancer and other 
extracranical tumors. The purpose of this presentation is to evaluate 
